Subsequent Events (Details) - USD ($) $ in Thousands				1 Months Ended	2 Months Ended	12 Months Ended		25 Months Ended
	Mar. 27, 2023	Mar. 03, 2023	Mar. 02, 2023	Feb. 14, 2023	Mar. 07, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Jan. 03, 2023	Dec. 16, 2022	Nov. 04, 2022	Dec. 31, 2020	Nov. 03, 2020	Jul. 15, 2019
Subsequent Event [Line Items]
Loss on the extinguishment of debt						$ 0	$ 13,822
Senior Secured Notes Due 2025
Subsequent Event [Line Items]
Interest rate						12.50%		12.50%
Debt instrument, amount redeemed										$ 1,882	$ 3,765
Senior Secured Notes Due 2025 | Senior Notes
Subsequent Event [Line Items]
Interest rate						12.50%		12.50%						12.50%
Loss on the extinguishment of debt							13,822
Long-term debt						$ 51,500		$ 51,500				$ 51,500	$ 70,000
Subsequent Event | Patent Litigation Settlement With BioDelivery Sciences International, Inc
Subsequent Event [Line Items]
Litigation settlement, amount awarded from other party		$ 8,500
Subsequent Event | Suboxone Agreements Settlement
Subsequent Event [Line Items]
Revenues			$ 11,482
Deferred revenue, revenue recognized			$ 5,482
Subsequent Event | Licensing and Supply Agreement with Pharmanovia
Subsequent Event [Line Items]
Revenues	$ 2,000
Subsequent Event | Senior Secured Notes Due 2025 | Senior Notes
Subsequent Event [Line Items]
Debt instrument, amount redeemed				$ 1,882					$ 3,765
Loss on the extinguishment of debt				352
Long-term debt				$ 45,853
At The Market Offering
Subsequent Event [Line Items]
Consideration received on sale of stock						$ 3,907	$ 29,778	$ 39,740
Number of shares issued in transaction (in shares)								10,341,957
At The Market Offering | Subsequent Event
Subsequent Event [Line Items]
Consideration received on sale of stock					$ 964
Number of shares issued in transaction (in shares)					1,078,622